American Conference
Institute (ACI) will be holding its 14th Advanced Forum on Biotech Patents on
November 28-29, 2012 in Boston, MA. The
conference will allow attendees to:
• Prepare for the
impending first-to-file regime and decide whether to file under the old or new
patent code;
• Analyze the
outcome in Prometheus and its impact
on personalized medicine;
• Determine the
implications of the Myriad case for subject matter patentability;
• Design systems to
rapidly respond to new post-grant and inter
partes review procedures;
• Explore ways in
which the Therasense decision has
changed how patent attorneys approach inequitable conduct concerns;
• Utilize superior
techniques to better protect antibodies and immunological innovations;
• Scrutinize the
recently issued biosimilars pathway regulations and craft a winning biologic
patenting strategy; and
• Assess how the
combined evolution of prior art obviousness and obvious-type double patenting
are influencing the future of secondary patents.
In particular,
ACI's faculty will offer presentations on the following topics:
• USPTO keynote: A
primer on the USPTO's efforts to implement the America Invents Act -- to be
presented by Teresa Stanek Rea, Deputy Director of the U.S. Patent &
Trademark Office;
• The sky is not
falling: Protecting your IP after Prometheus
and Myriad;
• Scrutinizing the
CAFC'S decisions in Akamai and McKesson and protecting technology in their
wake;
• The complete
guide to formulating a biosimilars patent strategy following the implementation
of the FDA's approval pathway;
• Overcoming the
challenges and grasping the opportunities presented by the PTO's new post-grant
review and inter partes review
procedures;
• Understanding the
obligations and defenses afforded biotech patent attorneys post-Therasense -- to be presented in part by
Patent Docs
author Dr. Kevin Noonan of McDonnell, Boehnen, Hulbert & Berghoff LLP;
• Producing a robust written description to satisfy
ever-shifting requirements and ensure patent validity;
• Crafting a global strategy: Best practices for
international prosecution and litigation to maximize the value of your biotech
patent portfolio; and
• Demystifying the current obviousness standard and
its implications for biotech patenting.
An interactive working group session entitled: "Integrating Changes at the PTO into Biotech Patent Practices" will be offered from 9:00 am to 12:00 pm on November 28, 2012. A post-conference master class entitled: "Successful and Practical Strategies for Patenting Antibodies" will be offered from 9:00 am to 12:00 pm on November 30, 2012.
The agenda for the Biotech Patents conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration
fee is $2,295 (conference alone), $2,995 (conference plus group session or master
class), or $3,495 (conference, group session, and master class). Those registering on or before September 27,
2012 will receive a $300 discount and those registering by October 26, 2012
will receive a $200 discount. Patent
Docs readers who reference the discount code "PD
200" will receive $200 off the current price tier when registering. Those
interested in registering for the conference can do so here,
by e-mailing [email protected] calling 1-888-224-2480, or
by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of ACI's Biotech Patents conference.
Comments